DB05904InvestigationalSmall molecule
BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and...
- Mechanism
- Curator reviewed
BLX-883 is the first clinical-stage therapeutic candidate produced in Biolex' GMP facilities using its proprietary Lex System.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C).Curator reviewed
- Code names
- BLX-883
What you can answer from here — as of April 02, 2025
Which companies are running trials of BLX-883, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account